Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Wilkinson JD, Sleeper LA, Alvarez JA, Bublik N, Lipshultz SE; for the Pediatric Cardiomyopathy Study Group. The pediatric cardiomyopathy registry: 1995–2007. Prog. Pediatr. Cardiol.25(1),31–36 (2008).
  MedlineGoogle Scholar
• 2  Lipshultz SE, Sleeper LA, Towbin JA et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med.348(17),1647–1655 (2003).▪ Found that the incidence of cardiomyopathy was significantly higher in children younger than 1 year old. The estimated incidence of pediatric cardiomyopathy was determined to be 1.13 cases per 100,000 children. Incidence varied according to sex, region and racial origin.
  MedlineGoogle Scholar
• 3  Bublik N, Alvarez JA, Lipshultz SE. Pediatric cardiomyopathy as a chronic disease: a perspective on comprehensive care programs. Prog. Pediatr. Cardiol.25(1),103–111 (2008).
  MedlineGoogle Scholar
• 4  Alvarez JA, Wilkinson JD, Lipshultz SE; for the Pediatric Cardiomyopathy Registry Study Group. Outcome predictors for pediatric dilated cardiomyopathy: a systematic review. Prog. Pediatr. Cardiol.23(1),25–32 (2007).
  MedlineGoogle Scholar
• 5  Towbin JA, Lowe AM, Colan SD et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA296(15),1867–1876 (2006).▪▪ Found that the annual incidence of dilated cardiomyopathy in children younger than 18 years of age was 0.57 cases per 100,000. It also found that annual incidence was higher in boys than girls. The majority of children had idiopathic disease, with the most common causes being myocarditis and neuromuscular disease.
  Medline CASGoogle Scholar
• 6  Towbin JA, Sleeper LA, Lowe AM et al. Etiology, incidence, and outcome of dilated cardiomyopathy in children: the pediatric cardiomyopathy registry experience. JAMA296(15),1867–1876 (2006).
  Medline CASGoogle Scholar
• 7  Fisher SD, Easley KA, Orav EJ et al. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV multicenter study. Am. Heart J.150(3),439–447 (2005).
  MedlineGoogle Scholar
• 8  Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients. N. Engl. J. Med.339(16),1153–1155 (1998).
  Medline CASGoogle Scholar
• 9  Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med.324,808–815 (1991).
  Medline CASGoogle Scholar
• 10  Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol.23,2629–2636 (2005).▪▪ Examined the course of left ventricular structure and function. Found that after 11.8 years, abnormalities of cardiac structure and function were persistent and progressive in children diagnosed with acute lymphoblastic leukemia treated with any amount of doxorubicin, but were particularly worse in children who received more than 300 mg/m2.
  Medline CASGoogle Scholar
• 11  Singh TP, Sleeper LA, Lipshultz SE et al. Association of left ventricular dilation at listing for heart transplant with post-listing and early post-transplant mortality in children with dilated cardiomyopathy. Circ. Heart Fail.2(6),591–598 (2009).
  Medline CASGoogle Scholar
• 12  Kantor PF, Orav EJ, Wilkinson JD et al. Progressive left ventricular changes predict the likelihood of survival in pediatric dilated cardiomyopathy: findings from the pediatric cardiomyopathy registry. Presented at: ACC Scientific Sessions. Chicago, IL, USA, 24–27 March 2012.
  Google Scholar
• 13  Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol.35(3),569–582 (2000).
  Medline CASGoogle Scholar
• 14  Rusconi PG, Ludwig DA, Ratnasamy C et al. Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. Am. Heart J.160(4),776–783 (2010).
  Medline CASGoogle Scholar
• 15  Harmon WG, Sleeper LA, Cuniberti L et al. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am. J. Cardiol.104(2),281–286 (2009).
  MedlineGoogle Scholar
• 16  Harmon WG, Sleeper LA, Cuniberti L et al. Practice patterns in treating children with dilated cardiomyopathy: findings from the North American Pediatric Cardiomyopathy Registry. Am. J. Cardiol.104(2),281–286 (2009).
  MedlineGoogle Scholar
• 17  Alvarez JA, Orav EJ, Wilkinson JD et al. Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the Pediatric Cardiomyopathy Registry. Circulation124(7),814–823 (2011).
  MedlineGoogle Scholar
• 18  Connuck DM, Sleeper LA, Colan SD et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the Pediatric Cardiomyopathy Registry. Am. Heart J.155(6),998–1005 (2008).
  MedlineGoogle Scholar
• 19  Wilkinson JD, Landy DC, Colan SD et al. The Pediatric Cardiomyopathy Registry and heart failure: key results from the first 15 years. Heart Fail. Clin.6(4),401–413 (2010).
  MedlineGoogle Scholar
• 20  Miyamoto SD, Stauffer BL, Nakano S et al. Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. Eur. Heart J. doi:10.1093/eurheartj/ehs229 (2012) (Epub ahead of print).
  MedlineGoogle Scholar
• 21  Lipshultz SE, Wilkinson JD. Beta-adrenergic adaptation in idiopathic dilated cardiomyopathy presenting in pediatric patients contrasted with adult presentations. Eur. Heart J. doi:10.1093/eurheartj/ehs402 (2012) (Epub ahead of print).
  MedlineGoogle Scholar
• 22  Pahl E, Sleeper LA, Canter CE et al. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. J. Am. Coll. Cardiol.59(6),607–615 (2012).
  MedlineGoogle Scholar
• 23  Larsen RL, Canter CE, Naftel DC et al. The impact of heart failure severity at time of listing for cardiac transplantation on survival in pediatric cardiomyopathy. J. Heart Lung Transplant.30(7),755–760 (2011).
  MedlineGoogle Scholar
• 24  Tsirka AE, Trinkaus K, Chen SC et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of cardiac transplantation. J. Am. Coll. Cardiol.44(2),391–397 (2004).
  MedlineGoogle Scholar
• 25  Foerster SR, Canter CE, Cinar A et al. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry. Circ. Heart Fail.3(6),689–697 (2010).
  MedlineGoogle Scholar
• 26  Pietra BA, Kantor PF, Bartlett HL et al. Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy. Circulation126(9),1079–1086 (2012).
  MedlineGoogle Scholar
• 27  Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation124(24),2761–2796 (2011).
  MedlineGoogle Scholar
• 28  Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J. Am. Coll. Cardiol.26(7),1699–1708 (1995).
  Medline CASGoogle Scholar
• 29  Maskatia SA. Hypertrophic cardiomyopathy: infants, children, and adolescents. Congenit. Heart Dis.7(1),84–92 (2012).
  MedlineGoogle Scholar
• 30  Decker JA, Rossano JW, Smith EO et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J. Am. Coll. Cardiol.54(3),250–254 (2009).
  MedlineGoogle Scholar
• 31  Colan SD, Lipshultz SE, Lowe AM et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation115(6),773–781 (2007).
  MedlineGoogle Scholar
• 32  Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J. Am. Coll. Cardiol.60(8),705–715 (2012).
  MedlineGoogle Scholar
• 33  Botvinick EH, Dae MW, Krishnan R, Ewing S. Hypertrophic cardiomyopathy in the young: another form of ischemic cardiomyopathy? J. Am. Coll. Cardiol.22(3),805–807 (1993).
  Medline CASGoogle Scholar
• 34  Garson A Jr. Sudden death in the young. Hosp. Pract. (Off. Ed.)26(6),51–60 (1991).
  MedlineGoogle Scholar
• 35  Gow RM. Sudden cardiac death in the young. Can. J. Cardiol.12(11),1157–1160 (1996).
  Medline CASGoogle Scholar
• 36  Liberthson RR. Sudden death from cardiac causes in children and young adults. N. Engl. J. Med.334(16),1039–1044 (1996).
  Medline CASGoogle Scholar
• 37  Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J. Am. Coll. Cardiol.5(Suppl. 6),B118–B121 (1985).
  MedlineGoogle Scholar
• 38  Lipshultz SE, Orav EJ, WIkinson JD et al. A risk stratification analysis of predictors of death or transplant in children with hypertrophic cardiomyopathy. Circulation118,S964, Abstract 4956 (2008).
  Google Scholar
• 39  Cox GF, Sleeper LA, Lowe AM et al. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics118(4),1519–1531 (2006).
  MedlineGoogle Scholar
• 40  Ho CY. New paradigms in hypertrophic cardiomyopathy: insights from genetics. Prog. Pediatr. Cardiol.31(2),93–98 (2011).
  MedlineGoogle Scholar
• 41  Wilkinson JD, Lowe AM, Salbert BA et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am. Heart J.164(3),442–448 (2012).▪▪ Compared children with Noonan syndrome and hypertrophic cardiomyopathy with children with idiopathic or familial hypertrophic cardiomyopathy. Found that children who had Noonan syndrome with hypertrophic syndrome had worse risk profiles. The authors suggested that an aggressive therapeutic approach, potentially including listing for cardiac transplantation, may be warrented.
  MedlineGoogle Scholar
• 42  Webber SA, Lipshultz SE, Sleeper LA et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation126(10),1237–1244 (2012).▪▪ Analyzed outcomes of children from the Pediatric Cardiomyopathy Registry with restrictive cardiomyopathy, with a focus on the impact of phenotype. Survival was found to be independent of phenotype, although children with the mixed restrictive cardiomyopathy and hypertrophic cardiomyopathy had significantly better transplant-free survival, whereas children with pure restrictive cardiomyopathy had worse transplant-free survival.
  MedlineGoogle Scholar
• 43  Maron BJ, Douglas PS, Graham TP, Nishimura RA, Thompson PD. Task Force 1: preparticipation screening and diagnosis of cardiovascular disease in athletes. J. Am. Coll. Cardiol.45(8),1322–1326 (2005).
  MedlineGoogle Scholar
• 44  Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J. Am. Coll. Cardiol.34(6),1813–1822 (1999).
  Medline CASGoogle Scholar
• 45  Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence – strategies to prevent sudden death. Fund. Am. Clin. Pharmacol.24(5),637–652 (2010).
  MedlineGoogle Scholar
• 46  Theodoro DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. J. Thorac. Cardiovasc. Surg.112(6),1589–1597; discussion 1597–1589 (1996).
  Medline CASGoogle Scholar
• 47  Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med.335(26),1933–1940 (1996).
  Medline CASGoogle Scholar
• 48  Lenarczyk R, Kowalski O, Kukulski T, Kowalczyk J, Kalarus Z. Resynchronization or dyssynchronization – successful treatment with biventricular stimulation of a child with obstructive hypertrophic cardiomyopathy without dyssynchrony. J. Cardiovasc. Electrophysiol.18(5),542–544 (2007).
  MedlineGoogle Scholar
• 49  Spirito P, Autore C, Rapezzi C et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation119(13),1703–1710 (2009).
  MedlineGoogle Scholar
• 50  Dadlani GH, Harmon WG, Perez-Colon E, Sokoloski MC, Wilmot I, Lipshultz SE. Diagnosis and screening of hypertrophic cardiomyopathy in children. Prog. Pediatr. Cardiol.31(1),21–27 (2011).
  Google Scholar
• 51  Rodday AM, Triedman JK, Alexander ME et al. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. Pediatrics129(4),e999–e1010 (2012).
  MedlineGoogle Scholar
• 52  Maron BJ, Zipes DP. 36th Bethesda Conference: eligibility recommendataions for competitive atheletes with cardiovascular abnormalities. J. Am. Coll. Cardiol.45(8),1313–1375 (2005).
  Google Scholar
• 53  Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation113(14),1807–1816 (2006).
  MedlineGoogle Scholar
• 54  Chen SC, Balfour IC, Jureidini S. Clinical spectrum of restrictive cardiomyopathy in children. J. Heart Lung Transplant.20(1),90–92 (2001).
  Medline CASGoogle Scholar
• 55  Keren A, Popp RL. Assignment of patients into the classification of cardiomyopathies. Circulation86(5),1622–1633 (1992).
  Medline CASGoogle Scholar
• 56  Russo LM, Webber SA. Idiopathic restrictive cardiomyopathy in children. Heart91(9),1199–1202 (2005).
  Medline CASGoogle Scholar
• 57  Denfield SW, Rosenthal G, Gajarski RJ et al. Restrictive cardiomyopathies in childhood. Etiologies and natural history. Tex. Heart Inst. J.24(1),38–44 (1997).
  Medline CASGoogle Scholar
• 58  Mogensen J, Kubo T, Duque M et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest.111(2),209–216 (2003).
  Medline CASGoogle Scholar
• 59  Angelini A, Calzolari V, Thiene G et al. Morphologic spectrum of primary restrictive cardiomyopathy. Am. J. Cardiol.80(8),1046–1050 (1997).
  Medline CASGoogle Scholar
• 60  Feld S, Caspi A. Familial cardiomyopathy with variable hypertrophic and restrictive features and common HLA haplotype. Isr. J. Med. Sci.28(5),277–280 (1992).
  Medline CASGoogle Scholar
• 61  Arbustini E, Morbini P, Grasso M et al. Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits. J. Am. Coll. Cardiol.31(3),645–653 (1998).
  Medline CASGoogle Scholar
• 62  Bergman JE, Veenstra-Knol HE, Van Essen AJ et al. Two related Dutch families with a clinically variable presentation of cardioskeletal myopathy caused by a novel S13F mutation in the desmin gene. Eur. J. Med. Genet.50(5),355–366 (2007).
  MedlineGoogle Scholar
• 63  Kaminska A, Strelkov SV, Goudeau B et al. Small deletions disturb desmin architecture leading to breakdown of muscle cells and development of skeletal or cardioskeletal myopathy. Hum. Genet.114(3),306–313 (2004).
  Medline CASGoogle Scholar
• 64  Li D, Tapscoft T, Gonzalez O et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation100(5),461–464 (1999).
  Medline CASGoogle Scholar
• 65  Silva CP, Bacal F, Benvenuti LA, Bocchi EA. Desmin-related restrictive cardiomyopathy. Arg. Bras. Cardiol.89(6),165–168 (2007).
  MedlineGoogle Scholar
• 66  Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog. Cardiovasc. Dis.51(1),58–73 (2008).
  MedlineGoogle Scholar
• 67  Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N. Engl. J. Med.336(4),267–276 (1997).
  Medline CASGoogle Scholar
• 68  Filopei J, Frishman W. Radiation-induced heart disease. Cardiol. Rev.20(4),184–188 (2012).
  MedlineGoogle Scholar
• 69  Bakalli A, Georgievska-Ismail L, Kocinaj D et al. Left ventricular and left atrial thrombi in sinus rhythm patients with dilated ischemic cardiomyopathy. Med. Arh.66(3),155–158 (2012).
  MedlineGoogle Scholar
• 70  Hirota Y, Kohriyama T, Hayashi T et al. Idiopathic restrictive cardiomyopathy: differences of left ventricular relaxation and diastolic wave forms from constrictive pericarditis. Am. J. Cardiol.52(3),421–423 (1983).
  Medline CASGoogle Scholar
• 71  Meaney E, Shabetai R, Bhargava V et al. Cardiac amyloidosis, contrictive pericarditis and restrictive cardiomyopathy. Am. J. Cardiol.38(5),547–556 (1976).
  Medline CASGoogle Scholar
• 72  Kantor PF, Rusconi P, Lipshultz S, Mital S, Wilkinson JD, Burch M. Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: summary from the second international conference on pediatric cardiomyopathy. Prog. Pediatr. Cardiol.32(1),11–14 (2011).
  MedlineGoogle Scholar
• 73  Leya FS, Arab D, Joyal D et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J. Am. Coll. Cardiol.45(11),1900–1902 (2005).
  Medline CASGoogle Scholar
• 74  Babuin L, Alegria JR, Oh JK, Nishimura RA, Jaffe AS. Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. J. Am. Coll. Cardiol.47(7),1489–1491 (2006).
  Medline CASGoogle Scholar
• 75  Sengupta PP, Krishnamoorthy VK, Abhayaratna WP et al. Comparison of usefulness of tissue Doppler imaging versus brain natriuretic peptide for differentiation of constrictive pericardial disease from restrictive cardiomyopathy. Am. J. Cardiol.102(3),357–362 (2008).
  Medline CASGoogle Scholar
• 76  Kaski JP, Syrris P, Burch M et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart94(11),1478–1484 (2008).
  Medline CASGoogle Scholar
• 77  Rivenes SM, Kearney DL, Smith EO, Towbin JA, Denfield SW. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation102(8),876–882 (2000).
  Medline CASGoogle Scholar
• 78  Kubo T, Gimeno JR, Bahl A et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J. Am. Coll. Cardiol.49(25),2419–2426 (2007).
  Medline CASGoogle Scholar
• 79  Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation101(21),2490–2496 (2000).
  Medline CASGoogle Scholar
• 80  Cetta F, O’Leary PW, Seward JB, Driscoll DJ. Idiopathic restrictive cardiomyopathy in childhood: diagnostic features and clinical course. Mayo Clin. Proc.70(7),634–640 (1995).
  Medline CASGoogle Scholar
• 81  Pignatelli RH, Mcmahon CJ, Dreyer WJ et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation108(21),2672–2678 (2003).
  MedlineGoogle Scholar
• 82  Tsai SF, Ebenroth ES, Hurwitz RA, Cordes TM, Schamberger MS, Batra AS. Is left ventricular noncompaction in children truly an isolated lesion? Pediatr. Cardiol.30(5),597–602 (2009).
  MedlineGoogle Scholar
• 83  Wald R, Veldtman G, Golding F, Kirsh J, McCrindle B, Benson L. Determinants of outcome in isolated ventricular noncompaction in childhood. Am. J. Cardiol.94(12),1581–1584 (2004).
  MedlineGoogle Scholar
• 84  Jenni R, Rojas J, Oechslin E. Isolated noncompaction of the myocardium. N. Engl. J. Med.340(12),966–967 (1999).
  Medline CASGoogle Scholar
• 85  Ergul Y, Nisli K, Demirel A et al. Left ventricular non-compaction in children and adolescents: clinical features, treatment and follow-up. Cardiol. J.18(2),176–184 (2011).
  MedlineGoogle Scholar
• 86  Dusek J, Ostadal B, Duskova M. Postnatal persistence of spongy myocardium with embryonic blood supply. Arch. Pathol.99(6),312–317 (1975).
  Medline CASGoogle Scholar
• 87  Sedmera D, Pexieder T, Vuillemin M, Thompson RP, Anderson RH. Developmental patterning of the myocardium. Anat. Rec.258(4),319–337 (2000).
  Medline CASGoogle Scholar
• 88  Towbin JA. Left ventricular noncompaction: a new form of heart failure. Heart Fail. Clin.6(4),453–469 (2010).
  MedlineGoogle Scholar
• 89  Martinez-Baca Lopez F, Alonso Bravo RM, Rodriguez Huerta DA. Echocardiographic features of non-compaction cardiomyopathy: missed and misdiagnosed disease. Arq. Bras. Cardiol.93(2),e33–e35 (2009).
  MedlineGoogle Scholar
• 90  Ozgur S, Senocak F, Orun UA et al. Ventricular non-compaction in children: clinical characteristics and course. Interact. Cardiovasc. Thorac. Surg.12(3),370–373 (2011).
  MedlineGoogle Scholar
• 91  Murphy RT, Thaman R, Blanes JG et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur. Heart J.26(2),187–192 (2005).
  MedlineGoogle Scholar
• 92  Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation82(2),507–513 (1990).
  Medline CASGoogle Scholar
• 93  Rosa LV, Salemi VM, Alexandre LM, Mady C. Noncompaction cardiomyopathy: a current view. Arq. Bras. Cardiol.97(1),e13–e19 (2011).
  MedlineGoogle Scholar
• 94  Zuckerman WA, Richmond ME, Singh RK, Carroll SJ, Starc TJ, Addonizio LJ. Left-ventricular noncompaction in a pediatric population: predictors of survival. Pediatr. Cardiol.32(4),406–412 (2011).
  MedlineGoogle Scholar
• 95  Richards A, Mao CY, Dobson NR. Left ventricular noncompaction: a rare cause of hydrops fetalis. Pediatr. Cardiol.30(7),985–988 (2009).
  MedlineGoogle Scholar
• 96  Ichida F, Tsubata S, Bowles KR et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation103(9),1256–1263 (2001).
  Medline CASGoogle Scholar
• 97  Sasse-Klaassen S, Probst S, Gerull B et al. Novel gene locus for autosomal dominant left ventricular noncompaction maps to chromosome 11p15. Circulation109(22),2720–2723 (2004).
  Medline CASGoogle Scholar
• 98  Vatta M, Mohapatra B, Jimenez S et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol.42(11),2014–2027 (2003).
  Medline CASGoogle Scholar
• 99  Weiford BC, Subbarao VD, Mulhern KM. Noncompaction of the ventricular myocardium. Circulation109(24),2965–2971 (2004).
  MedlineGoogle Scholar
• 100  Jenni R, Oechslin EN, Van Der Loo B. Isolated ventricular non-compaction of the myocardium in adults. Heart93(1),11–15 (2007).
  Medline CASGoogle Scholar
• 101  Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J. Am. Coll. Cardiol.36(2),493–500 (2000).
  Medline CASGoogle Scholar
• 102  Ichida F. Left ventricular noncompaction. Circ. J.73(1),19–26 (2009).
  Medline CASGoogle Scholar
• 103  Yasukawa K, Terai M, Honda A, Kohno Y. Isolated noncompaction of ventricular myocardium associated with fatal ventricular fibrillation. Pediatr. Cardiol.22(6),512–514 (2001).
  Medline CASGoogle Scholar
• 104  Ichida F, Hamamichi Y, Miyawaki T et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background. J. Am. Coll. Cardiol.34(1),233–240 (1999).
  Medline CASGoogle Scholar
• 105  Hamamichi Y, Ichida F, Hashimoto I et al. Isolated noncompaction of the ventricular myocardium: ultrafast computed tomography and magnetic resonance imaging. Int. J. Cardiovasc. Imaging17(4),305–314 (2001).
  Medline CASGoogle Scholar
• 106  Saito K, Ibuki K, Yoshimura N et al. Successful cardiac resynchronization therapy in a 3-year-old girl with isolated left ventricular non-compaction and narrow QRS complex: a case report. Circ. J.73(11),2173–2177 (2009).
  MedlineGoogle Scholar
• 107  Lofiego C, Biagini E, Pasquale F et al. Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. Heart93(1),65–71 (2007).
  Medline CASGoogle Scholar
• 108  Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med.344(7),501–509 (2001).
  Medline CASGoogle Scholar
• 109  Cavallo A, Joseph CJ, Casta A. Cardiac complications in juvenile hyperthyroidism. Am. J. Dis. Child.138(5),479–482 (1984).
  Medline CASGoogle Scholar
• 110  Cavallo A, Casta A, Fawcett HD, Nusynowitz ML, Wolf WJ. Is there a thyrotoxic cardiomyopathy in children? J. Pediatr.107(4),531–536 (1985).
  Medline CASGoogle Scholar
• 111  Gilbert-Barness E. Review: metabolic cardiomyopathy and conduction system defects in children. Ann. Clin. Lab. Sci.34(1),15–34 (2004).
  Medline CASGoogle Scholar
• 112  Jain V, Kannan L, Kumar P. Congenital hypopituitarism presenting as dilated cardiomyopathy in a child. J. Pediatr. Endocrinol. Metab.24(9–10),767–769 (2011).
  MedlineGoogle Scholar
• 113  Khochtali I, Hamza N, Harzallah O et al. Reversible dilated cardiomyopathy caused by hypothyroidism. Int. Arch. Med.4,20 (2011).
  Medline CASGoogle Scholar
• 114  Micallef T, Gruppetta M, Cassar A, Fava S. Takotsubo cardiomyopathy and severe hypothyroidism. J. Cardiovasc. Med. (Hagerstown)12(11),824–827 (2011).
  MedlineGoogle Scholar
• 115  McElhinney DB, Colan SD, Moran AM et al. Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics114(4),e452–e458 (2004).
  MedlineGoogle Scholar
• 116  Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics115(6),1613–1622 (2005).▪ Analyzed serial cardiac findings of anthracycline-treated childhood cancer survivors with several years of growth hormone therapy. Left ventricular contractility was decreased in patients who received growth hormone therapy before, during and after treatment. Although growth hormone therapy increased the wall thickness of the left ventricle, this effect was lost shortly after growth hormone therapy ended.
  MedlineGoogle Scholar
• 117  Ibe W, Saraste A, Lindemann S et al. Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment. Eur. J. Heart Fail.9(2),160–167 (2007).
  Medline CASGoogle Scholar
• 118  Kobayashi D, Cook AL, Williams DA. Progressively worsening hypertrophic cardiomyopathy in a child with newly diagnosed Costello syndrome while receiving growth hormone therapy. Cardiol. Young20(4),459–461 (2010).
  MedlineGoogle Scholar
• 119  Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev.17(3),325–344 (2012).
  Medline CASGoogle Scholar
• 120  Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy – fact or fiction? Herz36(2),102–115 (2011).
  Medline CASGoogle Scholar
• 121  Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol.48(3),173–181 (2011).
  MedlineGoogle Scholar
• 122  Von Bibra H, St John Sutton M. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia53(6),1033–1045 (2010).
  Medline CASGoogle Scholar
• 123  Grandi AM, Piantanida E, Franzetti I et al. Effect of glycemic control on left ventricular diastolic function in Type 1 diabetes mellitus. Am. J. Cardiol.97(1),71–76 (2006).
  Medline CASGoogle Scholar
• 124  Suys BE, Katier N, Rooman RP et al. Female children and adolescents with Type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care27(8),1947–1953 (2004).
  MedlineGoogle Scholar
• 125  Salem M, El Behery S, Adly A, Khalil D, El Hadidi E. Early predictors of myocardial disease in children and adolescents with Type 1 diabetes mellitus. Pediatr. Diabetes10(8),513–521 (2009).
  Medline CASGoogle Scholar
• 126  Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat. Clin. Pract. Cardiovasc. Med.4(8),436–443 (2007).
  Medline CASGoogle Scholar
• 127  Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation67(5),968–977 (1983).
  Medline CASGoogle Scholar
• 128  Mehta SK, Holliday C, Hayduk L, Wiersma L, Richards N, Younoszai A. Comparison of myocardial function in children with body mass indexes >/=25 versus those <25 kg/m² . Am. J. Cardiol.93(12),1567–1569 (2004).
  MedlineGoogle Scholar
• 129  Obert P, Gueugnon C, Nottin S et al. Two-dimensional strain and twist by vector velocity imaging in adolescents with severe obesity. Obesity (Silver Spring)20(12),2397–2405 (2012).
  MedlineGoogle Scholar
• 130  Unger RH. Lipotoxic disease. Annu. Rev. Med.53,319–336 (2002).
  Medline CASGoogle Scholar
• 131  Qureshi MY, Wilkinson JD, Lipshultz SE. The relationship of childhood obesity with cardiomyopathy and heart failure. In: Pediatric Metabolic Syndrome Comprehensive Clinical Review and Related Health Issues, Lipshultz SE, Messiah SE, Miller TL (Eds). Springer-Verlag, London, UK, 199–215 (2012).
  Google Scholar
• 132  Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat. Clin. Pract. Nephrol.3(12),637 (2007).
  MedlineGoogle Scholar
• 133  Anavekar NS, Mcmurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med.351(13),1285–1295 (2004).
  Medline CASGoogle Scholar
• 134  Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis.32(5 Suppl. 3),S112–S119 (1998).
  Medline CASGoogle Scholar
• 135  Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J. Pediatr.141(2),191–197 (2002).
  Medline CASGoogle Scholar
• 136  Shroff R, Weaver DJ Jr, Mitsnefes MM. Cardiovascular complications in children with chronic kidney disease. Nat. Rev. Nephrol.7(11),642–649 (2011).
  Medline CASGoogle Scholar
• 137  Mitsnefes MM, Barletta GM, Dresner IG et al. Severe cardiac hypertrophy and long-term dialysis: the Midwest Pediatric Nephrology Consortium study. Pediatr. Nephrol.21(8),1167–1170 (2006).
  MedlineGoogle Scholar
• 138  Gruppen MP, Groothoff JW, Prins M et al. Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int.63(3),1058–1065 (2003).
  MedlineGoogle Scholar
• 139  Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int.36(2),286–290 (1989).
  Medline CASGoogle Scholar
• 140  Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int.62(2),648–653 (2002).
  MedlineGoogle Scholar
• 141  Maron BJ. Sudden death in young athletes. N. Engl. J. Med.349(11),1064–1075 (2003).
  Medline CASGoogle Scholar
• 142  Amann K, Tyralla K, Gross ML et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int.63(5),1708–1713 (2003).
  Medline CASGoogle Scholar
• 143  Tyralla K, Adamczak M, Benz K et al. High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy. PLoS ONE6(1),e15287 (2011).
  MedlineGoogle Scholar
• 144  Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int.75(8),771–773 (2009).
  MedlineGoogle Scholar
• 145  Pilz S, Tomaschitz A, Marz W et al. Vitamin D, cardiovascular disease and mortality. Clin. Endocrinol. (Oxf.)75(5),575–584 (2011).
  Medline CASGoogle Scholar
• 146  Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Med. Sci.337(2),116–122 (2009).
  MedlineGoogle Scholar
• 147  Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation119(19),2545–2552 (2009).
  Medline CASGoogle Scholar
• 148  Holick MF. Vitamin D deficiency. N. Engl. J. Med.357(3),266–281 (2007).
  Medline CASGoogle Scholar
• 149  Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol.289(1),F8–F28 (2005).
  Medline CASGoogle Scholar
• 150  Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology149(2),558–564 (2008).
  Medline CASGoogle Scholar
• 151  Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J. Pediatr.154(6),906–911 e901 (2009).
  Medline CASGoogle Scholar
• 152  Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int.72(8),1004–1013 (2007).
  Medline CASGoogle Scholar
• 153  Maiya S, Sullivan I, Allgrove J et al. Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure. Heart94(5),581–584 (2008).
  Medline CASGoogle Scholar
• 154  Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med.168(15),1629–1637 (2008).
  MedlineGoogle Scholar
• 155  Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am. J. Kidney Dis.58(3),374–382 (2011).
  Medline CASGoogle Scholar
• 156  Sun Q, Shi L, Rimm EB et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am. J. Clin. Nutr.94(2),534–542 (2011).
  Medline CASGoogle Scholar
• 157  Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med.152(5),315–323 (2010).
  MedlineGoogle Scholar
• 158  Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int.71(1),31–38 (2007).
  Medline CASGoogle Scholar
• 159  Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med.349(5),446–456 (2003).
  Medline CASGoogle Scholar
• 160  Kovesdy CP. Survival benefits with vitamin D receptor activation: new insights since 2003. Clin. J. Am. Soc. Nephrol.5(9),1704–1709 (2010).
  Medline CASGoogle Scholar
• 161  Kim HW, Park CW, Shin YS et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin. Pract.102(1),c21–c29 (2006).
  MedlineGoogle Scholar
• 162  Mizobuchi M, Nakamura H, Tokumoto M et al. Myocardial effects of VDR activators in renal failure. J. Steroid Biochem. Mol. Biol.121(1–2),188–192 (2010).
  Medline CASGoogle Scholar
• 163  Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307(7),674–684 (2012).
  Google Scholar
• 164  Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin–angiotensin system. J. Clin. Invest.110(2),229–238 (2002).
  Medline CASGoogle Scholar
• 165  Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin–angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol.89–90(1–5),387–392 (2004).
  Medline CASGoogle Scholar
• 166  Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin–angiotensin systems. Am. J. Physiol. Endocrinol. Metab.288(1),e125–e132 (2005).
  Medline CASGoogle Scholar
• 167  Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl Acad. Sci. USA104(43),16810–16815 (2007).
  Medline CASGoogle Scholar
• 168  Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)₂D₃-dependent regulation of the renin–angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int.74(2),170–179 (2008).
  Medline CASGoogle Scholar
• 169  Yuan W, Pan W, Kong J et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem.282(41),29821–29830 (2007).
  Medline CASGoogle Scholar
• 170  Fryer RM, Rakestraw PA, Nakane M et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol.106(4),76–81 (2007).
  Google Scholar
• 171  Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr. Opin. Nephrol. Hypertens.21(1),72–79 (2012).
  Medline CASGoogle Scholar
• 172  Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II. Role of an intracardiac renin–angiotensin system. Annu. Rev. Physiol.54,227–241 (1992).
  Medline CASGoogle Scholar
• 173  Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin–angiotensin gene expression in the kidney by paricalcitol. Kidney Int.74(11),1394–1402 (2008).
  Medline CASGoogle Scholar
• 174  Wollert KC, Drexler H. The renin–angiotensin system and experimental heart failure. Cardiovasc. Res.43(4),838–849 (1999).
  Medline CASGoogle Scholar
• 175  Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int.78(10),975–980 (2010).
  Medline CASGoogle Scholar
• 176  Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med.359(6),584–592 (2008).
  Medline CASGoogle Scholar
• 177  Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J. Clin. Endocrinol. Metab.94(2),511–517 (2009).
  Medline CASGoogle Scholar
• 178  Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305(23),2432–2439 (2011).
  Google Scholar
• 179  Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr. Nephrol.27(11),2129–2136 (2012).
  MedlineGoogle Scholar
• 180  Isakova T, Houston J, Santacruz L et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr. Nephrol. doi:10.1007/s00467-013-2515-7 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 181  Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr. Nephrol.14(10–11),898–902 (2000).
  Medline CASGoogle Scholar
• 182  Borzych D, Bakkaloglu SA, Zaritsky J et al. Defining left ventricular hypertrophy in children on peritoneal dialysis. Clin. J. Am. Soc. Nephrol.6(8),1934–1943 (2011).
  MedlineGoogle Scholar
• 183  Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA. Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am. J. Cardiol.76(10),699–701 (1995).
  Medline CASGoogle Scholar
• 184  Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J. Am. Soc. Echocardiogr.22(6),709–714 (2009).
  MedlineGoogle Scholar
• 185  Bakkaloglu SA, Borzych D, Soo Ha I et al. Cardiac geometry in children receiving chronic peritoneal dialysis: findings from the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Clin. J. Am. Soc. Nephrol.6(8),1926–1933 (2011).
  MedlineGoogle Scholar
• 186  Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem.45(7),1005–1019 (1997).
  Medline CASGoogle Scholar
• 187  Liu L, Pasumarthi KB, Padua RR et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. Am. J. Physiol.268(5 Pt 2),H1927–H1938 (1995).
  Medline CASGoogle Scholar
• 188  Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest.121(11),4393–4408 (2011).
  Medline CASGoogle Scholar
• 189  Freundlich M, Li YC, Weisinger JR, Quiroz Y, Bravo J, Rodriguez-Iturbe B. Paricalcitol downregulates myocardial renin–angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. Am. J. Hypertens. doi:10.1093/ajh/hpt177 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 190  Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED. Elevated FGF-23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr. Nephrol.26(6),945–951 (2011).
  MedlineGoogle Scholar
• 191  Desjardins L, Liabeuf S, Renard C et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos. Int.23(7),2017–2025 (2012).
  Medline CASGoogle Scholar
• 192  Razzaque MS. The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol.5(11),611–619 (2009).
  Medline CASGoogle Scholar
• 193  Chen S, Gardner DG. Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. J. Steroid Biochem. Mol. Biol.136,150–155 (2012).
  MedlineGoogle Scholar
• 194  Davos CH, Doehner W, Rauchhaus M et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J. Card. Fail.9(1),29–35 (2003).
  MedlineGoogle Scholar
• 195  Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J. Am. Diet. Assoc.102(11),1621–1630 (2002).
  MedlineGoogle Scholar
• 196  Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids. J. Am. Diet. Assoc.100(6),637–640 (2000).
  Medline CASGoogle Scholar
• 197  Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its panel on folate, other B vitamins, and chlorine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. In: The National Academies Collection: Reports Funded by National Institutes of Health. National Academies Press, DC, USA (1998).
  Google Scholar
• 198  Electrolytes P.o.D.R.I.f., Water, and S.C.o.t.S.E.o.D.R. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. The National Academies Press, Washington, DC, USA (2005).
  Google Scholar
• 199  Trumbo P, Yates AA, Schlicker S, Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Diet. Assoc.101(3),294–301 (2001).
  Medline CASGoogle Scholar
• 200  Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; Food and Nutrition Board; Institute of Medicine. In: DRI Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academy Press, DC, USA (1997).
  Google Scholar
• 201  Broqvist M, Arnqvist H, Dahlstrom U, Larsson J, Nylander E, Permert J. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure – effects of long-term dietary supplementation. Eur. Heart J.15(12),1641–1650 (1994).
  Medline CASGoogle Scholar
• 202  Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz27(2),174–178 (2002).
  MedlineGoogle Scholar
• 203  Miller TL, Neri D, Extein J, Somarriba G, Strickman-Stein N. Nutrition in pediatric cardiomyopathy. Prog. Pediatr. Cardiol.24(1),59–71 (2007).
  MedlineGoogle Scholar
• 204  Szasz T, Thakali K, Fink GD, Watts SW. A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp. Biol. Med. (Maywood)232(1),27–37 (2007).
  Medline CASGoogle Scholar
• 205  Riccioni G, D’orazio N, Franceschelli S, Speranza L. Marine carotenoids and cardiovascular risk markers. Mar. Drugs9(7),1166–1175 (2011).
  Medline CASGoogle Scholar
• 206  Voutilainen S, Nurmi T, Mursu J, Rissanen TH. Carotenoids and cardiovascular health. Am. J. Clin. Nutr.83(6),1265–1271 (2006).
  Medline CASGoogle Scholar
• 207  Miwa K, Kishimoto C, Nakamura H et al. Serum thioredoxin and alpha-tocopherol concentrations in patients with major risk factors. Circ. J.69(3),291–294 (2005).
  Medline CASGoogle Scholar
• 208  Turan B, Vassort G. Vitamin E in oxidant stress-related cardiovascular pathologies: focus on experimental studies. Curr. Pharm. Des.17(21),2155–2169 (2011).
  Medline CASGoogle Scholar
• 209  Saremi A, Arora R. Vitamin E and cardiovascular disease. Am. J. Ther.17(3),e56–e65 (2010).
  MedlineGoogle Scholar
• 210  Little PJ, Bhattacharya R, Moreyra AE, Korichneva IL. Zinc and cardiovascular disease. Nutrition26(11–12),1050–1057 (2010).
  Medline CASGoogle Scholar
• 211  Strassburger M, Bloch W, Sulyok S et al. Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo. Free Radic. Biol. Med.38(11),1458–1470 (2005).
  Medline CASGoogle Scholar
• 212  Inge TH, Krebs NF, Garcia VF et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics114(1),217–223 (2004).
  MedlineGoogle Scholar
• 213  Frustaci A, Sabbioni E, Fortaner S et al. Selenium- and zinc-deficient cardiomyopathy in human intestinal malabsorption: preliminary results of selenium/zinc infusion. Eur. J. Heart Fail.14(2),202–210 (2012).
  Medline CASGoogle Scholar
• 214  Kosar F, Sahin I, Taskapan C et al. Trace element status (Se, Zn, Cu) in heart failure. Anadolu. Kardiyol. Derg.6(3),216–220 (2006).
  MedlineGoogle Scholar
• 215  Sirikonda NS, Patten WD, Phillips JR, Mullett CJ. Ketogenic diet: rapid onset of selenium deficiency-induced cardiac decompensation. Pediatr. Cardiol.33(5),834–838 (2012).
  MedlineGoogle Scholar
• 216  Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ. J.56(1),95–99 (1992).
  Medline CASGoogle Scholar
• 217  Schaffer SW, Jong CJ, Ramila KC, Azuma J. Physiological roles of taurine in heart and muscle. J. Biomed Sci.17(Suppl. 1),S2 (2010).
  MedlineGoogle Scholar
• 218  Ito T, Kimura Y, Uozumi Y et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J. Mol. Cell. Cardiol.44(5),927–937 (2008).
  Medline CASGoogle Scholar
• 219  Gesuete V, Ragni L, Picchio FM. The ‘big heart’ of carnitine. G. Ital. Cardiol. (Rome)11(9),703–705 (2010).
  MedlineGoogle Scholar
• 220  Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet. J. Rare Dis.7(1),68 (2012).
  MedlineGoogle Scholar
• 221  Baragou S, Pio M, Di Bernardo S et al. A cause of dilated cardiomyopathy in child: primary carnitine deficiency. Ann. Cardiol. Angeiol. (Paris) doi:10.1016/j.ancard.2011.12.006 (2011) (Epub ahead of print).
  MedlineGoogle Scholar
• 222  Benzarouel D, Hasni K, Ashab H, El Hattaoui M. [A reversible cause of cardiomyopathy: hypocalcemia]. Ann. Cardiol. Angeiol. (Paris) doi:10.1016/j.ancard.2012.04.003 (2012) (Epub ahead of print).
  Google Scholar
• 223  Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and Supplementation and relation to cardiovascular health. Am. J. Cardiol.109(3),359–363 (2012).
  Medline CASGoogle Scholar
• 224  Verma S, Khadwal A, Chopra K, Rohit M, Singhi S. Hypocalcemia nutritional rickets: a curable cause of dilated cardiomyopathy. J. Trop. Pediatr.57(2),126–128 (2011).
  MedlineGoogle Scholar
• 225  Cotran RM, Kumar V, Robbins SL. Robbin’s Pathologic Basis of Disease, 5th Edition. Michael B, Cohen MD (Eds). Elsevier, PA, USA (1994).
  Google Scholar